Observational Study to Evaluate Clinical Outcomes After First-Line Efavirenz-or Lopinavir-Ritonavir-Based HAART in Treatment-Naive Patients

Abstract

Purpose: To evaluate clinical, immunological, and virological outcomes after first-line highly active antiretroviral therapy (HAART) with a regimen including either efavirenz (EFV) or lopinavir/ritonavir (LPV/r) in treament-naive adult patients in routine clinical care.

Method: An ongoing prospective, observational follow-up study included all patients starting their first antiretroviral therapy (ART) with any of the studied regimens from July 1998 to July 2004. The follow-up period was finalized in September 2006, when all patients completed an observation of at least 96 weeks. Mortality rates, CD4 counts, viral suppression (HIV RNA below 50 copies/mL), and discontinuation of any component of the regimen were compared at 48 and 96 weeks.

Results: Despite the worst immunological status of the LPV/r group patients at baseline, this regimen was at least as effective as the one based on EFV not only in terms of treatment durability but also in terms of virological responses, nevertheless with an apparently quicker immune recovery. In general terms, both regimens present similar tolerability and safety outcomes except for the higher risk of increasing triglyceride (TG) levels in the LPV/r group. Low durability was observed in both regimens.

Conclusion: In a routine clinical care setting, initial HAART containing LPV/r seems to present an effectiveness, tolerability, and toxicity similar to the one containing EFV.

Keywords

HAART efavirenz (EFV)lopinavir/ritonavir (LPV/r)

References

Palella FJ, Jr , Delaney KM , Moorman AC , et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13): 853-860.

Schackman BR , Gebo KA , Walensky RP , et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care . 2006;44(11):990-997.

Yeni PG , Hammer SM , Hirsch MS , et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292(2): 251-265.

Arduino JM , Fischl MA , Stanley K. , Collier AC , Spiegelman D. Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection ? AIDS Res Hum Retroviruses. 2001;17(12): 1099-1105.

MS. and the Adult and Adolescent Spectrum of HIV Disease Project Investigators.. Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents. AIDS. 2001;15(14):1831-1836.

Panel de expertos de GESIDA Plan Nacional sobre el Sida. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2007) . Enferm Infecc Microbiol Clin. 2007;25(1):32-53.

Hammer SM , Saag MS , Schechter M. , et al., for the International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296(7): 827-843.

Gazzard B. , Bernard AJ , Boffito M. , et al., for the Writing Committee, British HIV Association. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7(8):487-503.

Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. 2006: 1-113. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentsGL.pdf. Accessed October 10, 2006.

10.

Echeverria P. , Carosi G. , Galves J. , et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/r, administered with abacavir/lamivudina, in naïve patients: a multicentre, randomized study. Proceedings of the 8th International Congress on Drug Therapy in HIV Infection ; 2006;8:Abstract No. P7.

11.

Riddler SA , Haubrich R. , DiRienzo AG , et al., and the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20): 2095-2106.

12.

Lindsay R. Beyond clinical trial: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis . Bone. 2007;40(5): S32-S35.

13.

Manfredi R. , Calza L. , Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naïve patients. AIDS. 2004;18(17): 2331-2333.

14.

Torti C. , Maggiolo F. , Patroni A. , et al. and the MASTER Cohort. Exploratory analysis for the evaluation of lopinavir/r-versus efavirenz-based HAART regimens in antiretroviral-naïve HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother. 2005;56(1):190-195.

15.

Panagopoulos P. , Tsiodras S. , Antoniadou A. , et al. Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. Clin Microbiol Infect. 2006;12(5):486-489.

16.

Mollet J. , Boivin J. Bias and confounding in pharmacoepidemiology. In: BL Strom , ed. Pharmacoepidemiology. 3rd ed. Chichester, UK: John Wiley & Sons; 2000: 765-784.

17.

Smith CJ , Cuthbertson Z. , Carroll A. , et al., Participation in clinical trials at the Royal Free Hospital: characteristics of those included and impact on treatment outcomes. Paper presented at: 10th Anniversary Conference of the British HIV Association [BHIVA]; April 15-17, 2004; City Hall, Cardiff, United Kingdom.

18.

Walmsley S. , Bernstein B. , King M. , et al. for the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346(26):2039-2046.

19.

Smith CJ , Phillips AN , Youle MS , et al. Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/r-containing antiretroviral regimens at the Royal Free Hospital. HIV Med. 2007;8(1):55-63.

20.

Smith CJ , Sabin CA , Youle MS , et al. Factors influencing increases in CD4 counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190(10):1860-1868.

21.

Dorrucci M. , Pezzotti P. , Grisorio B. , et al., for the Italian Cohort of Antiretroviral-Naïve Patients Study. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. AIDS. 2001;15(13): 1733-1736.

22.

Martinez E. , Arnaiz JA , Podzamczer D. , et al., and the Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med . 2003;349(11): 1036-1046.

23.

Aranzabal L. , Casado JL , Moya J. , et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis. 2005;40(4):588-593.